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The novel extended-spectrum -lactamase (ESBL) PME-1 wasfirst described in 2010 in an isolate from a Pseudomonas
aeruginosa strain obtained frommultiple clinical specimens from
a single patient admitted to the University of Pittsburgh Medical
Center in 2008. The patient had had a prolonged period of hospi-
talization in United Arab Emirates immediately before being
transferred to the United States (1).We describe here the first case
of P. aeruginosa carrying blaPME-1 isolated fromQatar and present
the second report to date of this enzyme.
The P. aeruginosaHZ-QTR-51 isolate was sent to the reference
laboratory at The University of Queensland Centre for Clinical
Research (UQCCR) as part of a region-wide collaborative study
onmultidrug-resistant Gram-negative bacilli (2, 3). The Etest was
used to measure the MIC of several antimicrobial compounds as
listed in Table 1.
The bacterial genomic DNAwas extracted using anUltraClean
Microbial DNA isolation kit (Mo Bio Laboratories). Species iden-
tification was performed using the PAduplex assay as previously
described (4). Paired-end libraries of whole genomic DNA of HZ-
QTR-51 were prepared via the use of a Nextera XT DNA sample
preparation kit and sequenced by the use of an Illumina HiSeq
platform (Illumina, San Diego, CA, USA). The 100-bp-paired-
end reads were de novo assembled using CLC Genomic Work-
bench with a minimum contig length of 200 bp. A total of 167
contigs were assembled with depth coverage of ca. 100.
The sequence type (ST) of P. aeruginosaHZ-QTR-51 was con-
firmed as ST 654 by in silico multilocus sequence typing (MLST)
(https://cge.cbs.dtu.dk/services/MLST/) (5). The ResFinder 2.1
platform (http://cge.cbs.dtu.dk/services/ResFinder/) (6) was also
used to characterize acquired antimicrobial resistancemechanism
genes among those in the draft genome. The isolate carried
blaPME-1 as well as blaOXA-50, blaGES-5, and blaPAO contributing to
-lactam resistance and strA, aph(3=)-VIa, aph(3=)-IIb, and strB
for aminoglycoside resistance. The isolate also carried fosA for
fosfomycin resistance, catB7 for chloramphenicol resistance, sul1
for sulfonamide resistance, and tet(A) and tet(G) for tetracycline
resistance. For further confirmation, blaPME-specific primers were
used as previously described (1).
P. aeruginosa HZ-QTR-51 was phenotypically resistant to all
tested antibiotics and was on the breakpoint border for amikacin
(Table 1). The carbapenem resistance in this isolate might be due
to the production of GES-5, which is a carbapenemase (7).
P. aeruginosa ST 654 is noteworthy for several reasons. VIM-
2-producing P. aeruginosa ST 654 was isolated from a patient in
Sweden following hospitalization in Tunisia (8). ST 654 was also
associated with KPC-producing P. aeruginosa fromArgentina (9).
More recently, VIM-2-producing P. aeruginosa ST 654 was iden-
tified among the international “high-risk clones” in the United
Kingdom (10). These reports highlight that P. aeruginosa ST 654 is
an internationally disseminated clone with a multidrug-resistant
phenotype, which might facilitate the rapid international spread
of PME-1 (and GES-5)-producing P. aeruginosa.
In conclusion, this report presents the first description of
PME-1-producing P. aeruginosa in Qatar and the second in the
world (11). The currently described P. aeruginosa isolate belongs
to successful international clone ST 654, which might contribute
to the global spread of multiple antibiotic resistance mechanisms,
including blaPME-1 and blaGES-5. We suggest active surveillance for
multidrug-resistant P. aeruginosa to assess the dissemination and
prevalence of beta-lactamase-mediated antibiotic resistance in the
Gulf region.
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TABLE 1 Antimicrobial MICs for PME-1-producing P. aeruginosa HZ-
QTR-51
Antimicrobial category Antimicrobial agent
MIC
(mg/liter)
EUCAST
interpretationa
Aminoglycosides Gentamicin 256 R
Amikacin 16 NS
Netilmicin 8 R
Antipseudomonal
penicillins and -
lactamase inhibitors
Ticarcillin/clavulanate 256 R
Piperacillin/tazobactam 32 R
Carbapenems Imipenem 32 R
Meropenem 32 R
Doripenem 32 R
Extended-spectrum
cephalosporins
Ceftazidime 32 R
Cefepime 16 R
Fluoroquinolones Ciprofloxacin 32 R
Monobactams Aztreonam 128 R
a R, resistant; NS, nonsusceptible.
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